Kahimmune Therapeutics is a cutting-edge biotech company focused on reexploring the cancer immunopeptidome to develop next-generation immuno-oncology therapies. Leveraging groundbreaking insights into the “dark genome”, Kahimmune identifies novel neoantigens to create innovative cancer vaccines designed for synergistic combination therapies.

Spun off from Gustave Roussy and SATT Paris-Saclay, Kahimmune leverages Kahinomics™, its proprietary neoantigen discovery platform, along with an exclusive IP portfolio. This integrated approach supports the creation of a robust pipeline targeting high‑burden cancers, including pancreatic and colorectal tumors.

Backed by an experienced founding team and strategic partnerships, Kahimmune is committed to advancing bold immunotherapy innovations that can transform cancer care.

Kahimmune Therapeutics

Org chart

Teams

Offices

Kahimmune Therapeutics

Org chart

Teams

Offices

Related companies